Moderna vs Regeneron Pharmaceuticals

Moderna (MRNA), health care, and Regeneron Pharmaceuticals (REGN), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Regeneron Pharmaceuticals is worth $99.2B on the stock market and Moderna $83.9B: Regeneron Pharmaceuticals is valued at 18% more. Moderna's operating margin in its latest fiscal year was -158% and Regeneron Pharmaceuticals's 24.9%. Over the past year Moderna's share price has moved +764% and Regeneron Pharmaceuticals's +31.3%.

Key facts

Moderna market value
$83.9B
Regeneron Pharmaceuticals market value
$99.2B
Regeneron Pharmaceuticals P/E
21.2
Moderna revenue
$1.9BFY to 2025-12-31
Regeneron Pharmaceuticals revenue
$14.3BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Moderna vs Regeneron Pharmaceuticals: every measure side by side
Measure Moderna Regeneron Pharmaceuticals
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$83.9Blower$99.2Bhigher
Revenue$1.9Blower$14.3Bhigher
Earnings-$2.8Blower$4.5Bhigher
Employees4,700lower15,410higher
Total assets$12.3Blower$40.6Bhigher
Valuation
P/E—21.2
P/S43.2higher6.9lower
P/B12.3higher2.9lower
Dividend yield0.00%lower0.39%higher
Profitability
Operating margin-158%lower24.9%higher
Balance sheet
Net assets$8.7Blower$31.3Bhigher
Total liabilities$3.7Blower$9.3Bhigher
Total debt$590Mlower$2Bhigher
Cash on hand$2.6Blower$3.1Bhigher
Price change
Today-3.65%lower+0.66%higher
1 year+764%higher+31.3%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio. Who owns MRNA · Who owns REGN

Further comparisons

Learn

Questions and answers

Which is bigger, Moderna or Regeneron Pharmaceuticals?

By market value, Regeneron Pharmaceuticals is the larger: $99.2B against $83.9B for Moderna. By revenue in its latest fiscal year, Regeneron Pharmaceuticals is the larger: $14.3B against $1.9B for Moderna.

Which has the higher operating margin?

Regeneron Pharmaceuticals: 24.9%, against -158% for Moderna. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Regeneron Pharmaceuticals: 0.39%, against 0.00% for Moderna. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Regeneron Pharmaceuticals: $2B, against $590M for Moderna. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Moderna and Regeneron Pharmaceuticals?

None of the tracked superinvestors holds both in their latest 13F filing. 2 hold Moderna and 10 hold Regeneron Pharmaceuticals.

Cite this page

Funkfolio, “Moderna vs Regeneron Pharmaceuticals”, data as of 17 November 2026. https://funkfolio.com/compare/mrna-vs-regn

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.